IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111393 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Taghreed A Ayash und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Ibnsina National College for Medical Studies, Jeddah 22421, Saudi Arabia. Hauptthemen laut MEDLINE: Chorioamnionitis, Cerebral Palsy, Autistic Disorder, Streptococcal Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Foundation of Stars, Montreal Children's Hospital Foundation.
Abstract (Originalsprache)
Group B Streptococcus (GBS) is one of the most common bacteria responsible for placental and neonatal infection and inflammation resulting in lifelong neurobehavioral impairments. In particular, GBS-induced chorioamnionitis is known in preclinical models to upregulate inflammatory pathways, primarily through the activation of the interleukin-1 (IL-1) pathway, leading to brain injury and subsequent neurodevelopmental issues. Previous studies from our laboratory using Lewis rat pups have shown that male offspring exposed in utero to GBS chorioamnionitis develop brain injuries leading to neurobehavioral impairments such as autistic traits. In the present study, we aimed to explore whether blocking the IL-1 pathway could prevent or mitigate these neurodevelopmental impairments in adulthood. Using our established preclinical model, we administered IL-1 receptor antagonist (IL-1Ra) to dams with GBS-induced chorioamnionitis. Here, we show that IL-1Ra administration to dams reversed autistic and cerebral palsy traits in male adult offspring exposed in utero to GBS. Hence, IL-1 blockade could serve as a therapeutic intervention against pathogen-induced neurodevelopmental disorders. This research supports the need for future human randomized controlled trials to assess IL-1 blockade administered during pregnancy or in newborns as a strategy to reduce the long-term neurobehavioral consequences of prenatal infections, such as autism, cerebral palsy, learning disabilities, and other neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Ibnsina National College for Medical Studies, Jeddah 22421, Saudi Arabia.
- Department of Pediatrics, Research Institute of the McGill University Health Centre, McGill University, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada.
ORCID-Profile: Taghreed A Ayash, Marie-Julie Allard, Mathilde Chevin
Förderung
- CIHR
- Foundation of Stars
- Montreal Children's Hospital Foundation
- France Canada Research Fund
- Dr. P. Lachapelle Fund
- Canadian Institute of Health Research
- Montreal Children’s Hospital Foundation
Zitieren
APA
Ayash, T. A., Allard, M. J., Chevin, M., & Sébire, G. (2024). IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111393
Vancouver
Ayash TA, Allard MJ, Chevin M, Sébire G. IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111393
BibTeX
@article{Ayash2024,
author = {Ayash, Taghreed A and Allard, Marie-Julie and Chevin, Mathilde and Sébire, Guillaume},
title = {IL-1 Blockade Mitigates Autism and Cerebral Palsy Traits in Offspring In-Utero Exposed to Group B Streptococcus Chorioamnionitis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111393}
}
EUVIMED